Coprevalence of tremor with spasmodic dysphonia: A case-control study

Laryngoscope

Volumn 121, Issue 8, 2011, Pages 1752-1755

  White, Laura J ^a   Klein, Adam M ^b   Hapner, Edie R ^b   Delgaudio, John M ^b   Hanfelt, John J ^c   Jinnah, Hyder A ^d   Johns III, Michael M ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Spasmodic dysphonia; tremor; vocal tremor

Indexed keywords

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DYSTONIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SPASMODIC DYSPHONIA; TREMOR; VOCAL TREMOR;

AGED; CASE-CONTROL STUDIES; DYSPHONIA; FEMALE; HUMANS; MALE; MIDDLE AGED; TREMOR;

EID: 79960943811     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.21872     Document Type: Article

References (12)

1. Svetel M, Pekmezovic T, Jovic J, et al. Spread of primary dystonia in relation to initially affected region. J Neurol 2007; 254: 879-883. (Pubitemid 47222308)
2. Blitzer A, Brin MF, Stewart CF,. Botulinum toxin management of spasmodic dysphonia: a 12-year experience in more than 900 patients. Laryngoscope 1998; 108: 1435-1441. (Pubitemid 28465236)
3. Kendall KA, Leonard RJ,. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor. J Voice 2011; 25: 114-119.
4. Blitzer A, Brin MF, Fahn S, Lovelace RE,. Clinical and laboratory characteristics of focal laryngeal dystonia: study of 110 cases. Laryngoscope 1998; 96: 636-640.
5. Louise ED, Benito-Leon J, Ottman R, Bermejo-Pareja F,. A population-based study of mortality in essential tremor. Neurology 2007; 69: 1982-1989. (Pubitemid 350145090)
6. Lorenz D, Deuschl G,. Update on pathogenesis and treatment of essential tremor. Curr Opin Neurol 2007; 20: 447-452. (Pubitemid 47051993)
7. Aronson AE, Brown JR, Litin EM, Pearson JS,. Spastic dysphonia II. Comparison with essential (voice) tremor and other neurologic and psychogenic dystonias. J Speech Hear Disord 1968; 33: 219-231.
8. Rincon F, Louis ED,. Benefits and risks of pharmacological and surgical treatments for essential tremor: disease mechanisms and current management. Expert Opin Drug Saf 2005; 4: 899-913. (Pubitemid 41257991)
9. Wenning GK, Kiechl S, Seppi K, et al. Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. Lancet Neurol 2005; 4: 815-820. (Pubitemid 41619436)
10. Adler CH, Bransberg SF, Bents JG, et al. Botulinum toxin type A for treating voice tremor. Arch Neurol 2004; 61: 1416-1420. (Pubitemid 39202225)
11. Koller WC, Glatt S, Biary N, Rubino FA,. Essential tremor variants: effect of treatment. Clin Neuropharmacol 1987; 10: 342-350. (Pubitemid 17113904)
12. Findley LJ, Gresty MA,. Head, facial, and voice tremor. In:, Jankovic J, Tolosa E, eds. Advances in Neurology: Facial Dyskinesias. Vol 49. New York, NY: Raven Press; 1988: 239-253.